Search: (WFRF:(Rujescu Dan)) lar1:(lu) >
Amyloid blood bioma...
Amyloid blood biomarker detects Alzheimer's disease
-
- Nabers, Andreas (author)
- Ruhr-University Bochum
-
- Perna, Laura (author)
- German Cancer Research Centre
-
- Lange, Julia (author)
- Ruhr-University Bochum
-
show more...
-
- Mons, Ute (author)
- German Cancer Research Centre
-
- Schartner, Jonas (author)
- Ruhr-University Bochum
-
- Güldenhaupt, Jörn (author)
- Ruhr-University Bochum
-
- Saum, Kai Uwe (author)
- German Cancer Research Centre
-
- Janelidze, Shorena (author)
- Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Holleczek, Bernd (author)
- Saarland Cancer Registry
-
- Rujescu, Dan (author)
- Martin-Luther-Universität Halle-Wittenberg
-
- Hansson, Oskar (author)
- Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Gerwert, Klaus (author)
- German Cancer Research Centre
-
- Brenner, Hermann (author)
- German Cancer Research Centre,Heidelberg University
-
show less...
-
(creator_code:org_t)
- 2018-04-06
- 2018
- English.
-
In: EMBO Molecular Medicine. - : EMBO. - 1757-4676 .- 1757-4684. ; 10:5
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid-β (Aβ) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross-sectional BioFINDER cohort. In a further population-based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Biomedicinsk laboratorievetenskap/teknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Biomedical Laboratory Science/Technology (hsv//eng)
Keyword
- Alzheimer's disease diagnosis
- Amyloid-β in blood plasma
- BioFINDER
- ESTHER
- Immuno-infrared-sensor
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Nabers, Andreas
-
Perna, Laura
-
Lange, Julia
-
Mons, Ute
-
Schartner, Jonas
-
Güldenhaupt, Jör ...
-
show more...
-
Saum, Kai Uwe
-
Janelidze, Shore ...
-
Holleczek, Bernd
-
Rujescu, Dan
-
Hansson, Oskar
-
Gerwert, Klaus
-
Brenner, Hermann
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Medical Biotechn ...
-
and Biomedical Labor ...
- Articles in the publication
-
EMBO Molecular M ...
- By the university
-
Lund University